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Summary 2,3,5-Trimethyl-6-(3-pyridylmethyl) 1,4-benzoquinone (CV-6504), an inhibitor of 5-lipoxygenase, effectively suppressed growth of
the MAC16 tumour in vivo and prevented the accompanying cachexia, when administered daily at a dose of 10 mg kg-'. There was a
reduction in the tumour concentration of linoleic (LA), arachidonic (AA), oleic, stearic and palmitic acid. In order to elucidate the mechanism of
the anti-tumour action, the effect of CV-6504 on the metabolism of AA through the 5-, 12- and 15-lipoxygenase pathways has been
determined in cell lines sensitive (MAC16, MAC13, MAC26 and Caco-2) and resistant (A549 and DU-145) to CV-6504. Incubation of all cell
lines with [3H]AA led to the appearance of [3H]5-, 12- and 15-HETE. Preincubation of MAC16, MAC13, MAC26 and Caco-2 with 10 gM CV-
6504 inhibited the conversion of AA to 5-, 12- and 15-HETE, while in A549 and DU-145 cells there was no effect on metabolism through any
lipoxygenase pathway. Two other cell lines, MDA-MB-231 and PC-3, sensitive to growth inhibition by CV-6504, are known to require LA for
growth, while DU-145, which was insensitive to growth inhibition by CV-6504, showed no growth response to LA. These results suggest that
some tumours are dependent on lipoxygenase metabolites of LA and AA for their continual growth, and interference with this pathway
produces a specific growth inhibition.
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2,3,5-Trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone (CV-6504)
is a dual thromboxane A2 synthase and 5-lipoxygenase inhibitor
with IC50 values against both enzymes of 10-7M (Ohkawa et al,
1991). It also displays scavenging activity against active oxygen
species and was designed to protect against glomerular injury and
proteinuria, which is thought to involve the mediation of all three
pathways (Shibouta et al, 1991). We have recently shown CV-6504
to exert profound anti-tumour activity against three murine adeno-
carcinomas (MAC16, MAC13 and MAC26), which are generally
refractory to cytotoxic agents (Hussey et al, 1996). This compound
is to undergo clinical evaluation against pancreatic carcinoma. In
mice, anti-tumour activity was reduced by concomitant administra-
tion of linoleic acid (LA), suggesting that the anti-tumour effect
may be mediated through inhibition of the metabolism of this
polyunsaturated fatty acid (PUFA).
PUFAs, and LA in particular, have been implicated as tumour
promoters (Reddy and Masura, 1984), as enhancers of metastasis
(Rose et al, 1991) and as stimulators of tumour growth in vitro
(Wicha et al, 1979) and in vivo (Hussey and Tisdale, 1994). These
effects are probably due to metabolism of LA to prostaglandins or
products of the lipoxygenase pathways. Buckman et al (1991),
using a murine mammary carcinoma cell line, attributed the
growth-stimulatory effect of LA in vitro to metabolites of the
lipoxygenase rather than the cyclo-oxygenase pathway.
Lipoxygenase enzymes catalyse reactions between oxygen and
PUFAs containing the non-conjugated 1,4 cis, cis-pentadiene
structure to form hydroperoxides, which can undergo reduction to
form hydroxyeicosatetraenoic acids (HETE). The three regio
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isomers, 5-, 12- and 15-HETE, are produced fromarachidonic acid
(AA) via the corresponding lipoxygenase enzymes. Lipoxygenase
products of either arachidonic acid (AA) or LA act to stimulate
cellular proliferation either directly (Bandyopadhyay et al, 1988)
or indirectly as intermediaries in the mitogenic effect of growth
factors, such as epidermal growth factor (EGF) (Eling and
Glasgow, 1994). In addition, 12-HETE has been suggested as an
important determinant of the metastatic potential of tumour cells
(Liu et al, 1994).
These results suggest that CV-6504 may exert its anti-tumour
activity as a result ofthe inhibition of a lipoxygenase pathway. In
the present investigation, the effect of CV-6504 on the lipoxyge-
nase pathways ofcell lines with varying sensitivity to growth inhi-
bition by this agent has been evaluated.
MATERIALS AND METHODS
Animals
Pure strain female NMRI mice obtained from our own inbred
colony were transplanted with fragments ofthe MAC16 tumourby
trocar into the flank as previously described (Bibby et al, 1987).
Therapy was initiated 9-12 days after transplantation when the
tumour became palpable and weight loss had started to occur. CV-
6504 was supplied by Takeda Chemical Industries Ltd, Osaka,
Japan and was administered p.o. daily in aqueous solution (0.1
ml). Control mice received water alone (0.1 ml). Both tumour
volume and the body weight ofmice were measured daily.
Cell lines
MAC16, MAC13 and MAC26 cell lines were derived from the
solid tumours and were maintained in vitro in RPMI-1640 medium
supplemented with either 5% (MAC16) or 10% (MAC13 and
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MAC26) fetal calf serum (FCS) at 37°C under an atmosphere of
5% carbon dioxide in air. Human prostatic carcinoma cells, PC-3
and DU-145, were also maintained in RPMI-1640 containing 5%
FCS. Human lung carcinoma A549 cells were grown in nutrient
mixture F-12 HAM with glutamine and supplemented with 10%
FCS. Human colonic carcinoma Caco-2 cells and human breast
carcinoma MDA-MB-231 cells were grown in Dulbecco's modi-
fied eagle medium (DMEM) supplemented with 10% FCS. All
cell lines grew as a monolayer, except for MAC16, which grew in
suspension culture. For cell growth assays, cells were seeded
either at 0.5 (MAC13, MAC26, A549, PC-3, DU-145 and MDA-
MB-231) or 2.0 x 104 cells per well (MAC16 and Caco-2) and left
for 2 h before drug addition. CV-6504 was dissolved in water. Cell
numbers were determined 72 h after drug addition using a Coulter
Counter model ZM.
Fatty acid analysis
Total lipids were extracted from tumour and liverby the method of
Folch et al (1957). Samples were homogenized in 10 volumes of
chloroform:methanol (2:lv/v) containing an internal standard of
margaric acid (50 jig) and butylated hydroxytoluene (0.01 volume
dissolved in 50% ethanol). Organic and aqueous layers were sepa-
rated by the addition of0.2 volumes ofdistilled water and 1 ml of
methanol, followed by centrifugation at 1500 g for 5 min. The
organic layer was saponified by heating to 100°C in 2.5 ml of 5%
sodium hydroxide in 50% methanol under nitrogen for45-60 min.
The samples were cooled and acidified to pH 2 with concentrated
hydrochloric acid. The extracted fatty acids were then methylated
by heating to 90°C for 5 min with 14% BF3 in methanol. The
cooled mixture was then extracted twice with 2 ml of hexane:
chloroform (4:1, v/v). The fatty acid methyl esters were analysed
using a Hewlett Packard 5890 Series II gas-liquid chromatograph
connected to a Hewlett Packard HP3396A integrator. The gas
chromatograph was fitted with a 30 m DB-23 narrow bore capil-
lary column. The injector temperature was set at 190°C and the
flame ionization detector at 240°C. The column head pressure was
at 21 psi, with a split ratio of between 5 and 8 m min-'. Samples
were run on a temperature-programmed run with the initial
temperature at 180°C for 5 min, followed by a 5°C per min rise in
temperature to 220°C, which was held for 15 min. The peaks were
identified by comparison of the retention times with those of
authentic standards.
Analysis of lipoxygenase metabolites of arachidonate
Cells (5 x 106) were incubated with CV-6504 for 24 h before
labelling in RPMI-1640 media containing normal serum levels.
The cells were washed with phosphate-buffered saline (PBS) and
resuspended in fresh medium containing 2.5 ,uCi of [3H]arachi-
donic acid (specific activity 8.18 TBq mmol-1; Du Pont, Herts UK)
and mixed with unlabelled arachidonic acid to a final concentra-
tion of 10gM. After 30 min (A549), lh (Caco-2 and DU-145) or 2
h (MAC16, MAC13 and MAC26) at 370C, the incubation was
terminated by the addition of IN hydrochloric acid to acidify the
cell suspension to pH 3.5. These time intervals were chosen to
allow maximum incorporation of [3H]arachidonic acid into the
cells. The cells were separated by low-speed centrifugation (1500
x g, 10 min) and were washed twice with PBS. The cells were
resuspended in PBS (0.8 ml) and sonicated for 4 x 15 s on ice. The
solution was acidified to pH 3.5 with IN hydrochloric acid and
chloroform: methanol (1:2, v/v) (3 ml) was added, followed by
vigorous mixing for 1 min. After 30 min at room temperature,
chloroform (1 ml) was added, and, after vigorous mixing, was
followed by the addition of 0.OOiN hydrochloric acid (1 ml) and
vortexing for another 10 s. After centrifugation at 2000 x g for 20
min at 4'C, the chloroform layer was removed and the aqueous
phase was re-extracted with chloroform (2 ml). The combined
chloroform extracts were evaporated under a stream of nitrogen
and the residue was dissolved in acetonitrile (0.1 ml) and stored
under argon at -70°C in the absence of light. Cell lipids were
analysed by reversed-phase high-performance liquid chromatog-
raphy (RP-HPLC) with a Waters j Bondapak C18 column (3.9 x
300 mm) by an isocratic elution at 1.5 ml min-' with 58% acetoni-
trile:water:acetic acid (20:100:0.05 v/v) and 42% acetonitrile -
acetic acid. (100:0.05 v/v) (Liu et al, 1994). Radioactivity and
ultraviolet absorbance at 237 nm were monitored Peaks were
identified based on the retention times of authentic 5-, 12- and
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Figure 1 Effect of daily administration of CV-6504 (10 mg kg-1) (LI) on
tumour growth (A) and weight loss (B) in female NMRI mice (n = 9 per group)
bearing the MAC16 tumour. Control animals (X) received water alone. Both
tumour volume and host body weight were normalized to 100% on day 1,
the start of the experiment. A dose of 10 mg kg-' CV-6504 has previously
been shown to be optimal against the MAC16 tumour in male mice (Hussey
et al, 1996). Differences from control values are shown as a, P< 0.05 and b,
P< 0.01
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Figure 2 Effect of daily administration of CV-6504 (10 mg kg-') for 7 days
on the fatty acid profile of control (a-1) and treated (1) tumour (A) and liver
(B). Differences from control values are shown as ap < 0.05 and bp < 0.01
Table 1 Effect of CV-6504 on growth of cell lines in vitro
Cell line IC50 (pm)"
MAC13 3±1
MAC16 3±1
MAC26 7±1
A549 61 ±1
Caco-2 5 ±0
MDA-MB-231 10 ±1
PC-3 17±0
DU-145 70±0
aConcentration producing 50% inhibition of cell growth over a 72-h period.
The values are averages of nine determinations.
15-HETE (Sigma Chemical Co., Poole, Dorset, UK). The amounts
ofHETEs were quantified based on the specific activity ofradiola-
belled arachidonic acid and the ratio ofradiolabelled to unlabelled
substrate.
Statistical analysis
Results are presented as means ± s.e.m. The data were statistically
evaluatedusing two-way analysis ofvariance followedbyTukey's test.
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Figure 3 The effect of 10 rm CV-6504 on the metabolism of AA to 5-, 12-
and 15-HETE in (A) MAC13 (El), MAC16 (IS), MAC26 (U) and (B) A549 (LI),
Caco-2 (IS) and DU-145 (U). The top box for each cell line represents the
control and the bottom box the treated cells. The experiment was repeated
four times. Differences from controls are shown as ap < 0.05 and bp < 0.01
RESULTS
Growth ofthe MAC16 tumour in NMRI mice is accompanied by a
progressive cachexia, which increases as tumour growth increases
(Beck and Tisdale, 1987). The effect ofdaily oral administration of
CV-6504 (10 mg kg-') on tumour growth and cachexia in this
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murine model in female NMRI mice is shown in Figure IA and B.
Although the tumour was already established when therapy was
initiated, CV-6504 produced a reduction in tumour volume from
day 11 (Figure lA) and this was accompanied by a significant
reduction in hostbody weight loss, which was significant from day
13 (Figure iB). Since the control animals had to be terminated
owing to cachexia on day 15, CV-6504 effectively prolonged the
survival ofmice bearing this tumour.
Since CV-6504 may be expected to interfere with lipid metabo-
lism, the effect ofthis agent administered daily for 7 days at 10 mg
kg-' on the fatty acid composition ofthe liver and the tumour was
investigated (Figure 2A and B). CV-6504 reduced the total fatty
acid content of the liver with specific reductions in AA, LA and
oleic acid (OA) (Figure 2A). The total fatty acid content of the
tumour was also significantly reduced with specific reductions in
AA, LA, OA, stearic and palmitic acids (Figure 2B). These results
confirm that CV-6504 modulates fatty acid metabolism in vivo.
Further mechanistic studies were performed on cells in vitro.
The effect ofCV-6504 on the growth ofmurine and human colon,
breast, lung and prostatic tumours is shown in Table 1. The sensi-
tivity varied between the cell lines with human colon (Caco-2),
breast (MDA-MB-231) and prostate (PC-3) being of the same
order as for the MAC cell lines. In contrast, the human lung
(A549) and prostate (DU-145) were more resistant with IC50
values for CV-6504 being ofthe order oftenfold greater.
In order to investigate mechanisms ofsensitivity and resistance,
the effect of CV-6504 on the metabolism of AA has been investi-
gated in the three human cell lines, A549, DU-145 and Caco-2,
and compared with that in the MAC cell lines, MAC16, MAC13
and MAC26. All six cell lines showed detectable formation of5-,
12- and 15-HETE from a pulse of [3H]AA (Figure 3). However,
the level of incorporation of [3H]AA was low for MAC16, and
both DU-145 and A549 also showed a low level of formation of
5-, 12- and 15-HETE. For most cell lines, the distribution of AA
between the 5-, 12- and 15-lipoxygenase pathways was approxi-
mately the same, although 5-HETE formation exceeded the 12-
and 15-HETE in MAC13 cells. The effect of preincubation with
10 gM CV-6504 on the metabolism of AA through the lipoxyge-
nase pathways is also shown in Figure 3. In cell lines sensitive to
growth inhibition by CV-6504, MAC16, MAC13, MAC26 and
Caco-2, there was a significant reduction in 5-, 12- and 15-HETE
production, and for MAC16, MAC13 and Caco-2, a significant
reduction in unmetabolized AA recovered relative to untreated
cells. At a concentration of 10gM, CV-6504 had no effect on either
5-, 12- or 15-HETE production in either A549 or DU-145 cells.
DISCUSSION
The sensitivity ofthe various cell lines to growth inhibition by CV-
6504 appears to correlate with the requirement of LA for growth.
Thus, MAC cell lines have been shown to undergo growth stimu-
lation by LA both in vitro and in vivo (Hussey and Tisdale, 1994)
and these cell lines show low IC50 values for CV-6504. The
oestrogen-independent human breast cancer cell line, MDA-MB-
231, is also sensitive to CV-6504. LA has been shown to stimulate
proliferation of this cell line (Rose and Connolly, 1989), and this
was dependent on the products of lipoxygenase rather than cyclo-
oxygenase pathways (Rose and Connolly, 1990). When this cell
line was transplanted into nude mice, diets rich in n-3 PUFAs
reduced both tumour growth and metastasis, and this was found to
correlate with a three- to four-fold reduction in 12- and 15-HETE
production (Rose et al, 1995). Growth of the androgen-unrespon-
sive prostatic cancer cell line, PC-3, was shown to be stimulated in
vitro by LA, while DU-145, which is also androgen unresponsive,
showed no growth response to LA (Rose and Connolly, 1991). In
this study, we have shown CV-6504 to have IC50 values of 17 and
70gM against the cell lines PC-3 and DU-145 respectively.
The effect ofCV-6504 on PUFA metabolism has been examined
by determining the effect on conversion of AA to 5-, 12- and 15-
HETE in MAC16, MAC13, MAC26, Caco-2, DU-145 and A549
cell lines. Both A549 and DU-145 were relatively resistant to
growth inhibition by CV-6504 in comparison with the other cell
lines. At a concentration of 10 gM, CV-6504 was capable of
causing significant inhibition of 5-, 12- and 15-HETE production
in MAC16, MAC13, MAC26 and Caco-2 cells, but in both A549
and DU-145, metabolism ofAA through the 5-, 12- and 15-lipoxy-
genase pathways was not affected by this concentration of CV-
6504. Thus, the IC50 values for CV-6504 against these five cell
lines correlate with the inhibition of AA metabolism through the
three lipoxygenase pathways.
Although CV-6504 was designed as a specific 5-lipoxygenase
inhibitor (Ohkawa et al, 1991), these results show that it is also
capable of profound inhibition of both the 12- and 15-lipoxyge-
nase pathways in sensitive tumour cell lines. Another agent
inhibiting tumour proliferation, eicosapentaenoic acid (EPA) has
been shown to reduce the tumour concentration of 12- and 15-
HETE, while the level of 5-HETE was unaffected (Rose et al,
1995). These results suggest that inhibition of 12- and/or 15-
lipoxygenases may be most important for tumour growth inhibi-
tion, and some 5-lipoxygenase inhibitors may show anti-tumour
activity as a result ofcross-reactivity towards these pathways.
12-HETE has been shown to stimulate DNA synthesis in fetal
bovine aortic endothelial cells (Setty et al, 1987), which is
possibly mediatedthrough diacylglycerol kinase inhibition and the
concomitant accumulation of cellular diacylglycerol. This may
explain the ability of 12-HETE to activate protein kinase C in
tumour cells by stimulating translocation ofthe enzyme to the cell
membrane (Honn et al, 1994). 12-HETE may also mediate
EGF/insulin-stimulated DNA synthesis in neonatal rat lens epithe-
lial cells by regulating proto-oncogene expression (Lysz et al,
1994). Friend erythroleukaemic cells in logarithmic phase metabo-
lize higher concentrations of 15-HETE compared with cells in
stationary phase (Postaok et al, 1990). If 15-HETE production is
inhibited, DNA synthesis is also inhibited, suggesting a role for
15-HETE in the proliferation ofthese cells.
Thus, some, but not all, tumours appear to depend on these
metabolites of AA for their continual proliferation. Such tumours
may be expected to display sensitivity towards CV-6504. Even
more effective anti-tumour agents could be generated by specific
inhibitors ofthe 12- and/or 15-lipoxygenase pathways.
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